Omega-3 supplements protect the brain’s breathing center in Parkinson’s disease model

Omega-3 fish oil supplements preserved the brain regions that control breathing and restored normal breathing rates in mice with a Parkinson’s disease-like condition, according to new research published in the journal Neuroscience.

Parkinson’s disease is a brain disorder known for causing tremors, stiffness, and slow movement—symptoms that stem from the gradual death of dopamine-producing brain cells. In the advanced stages of the disease, many patients develop impaired breathing, and pneumonia resulting from this is the leading cause of death. These breathing problems are thought to arise because the disease eventually damages specific regions of the brainstem controlling automatic functions like breathing and heart rate.

Despite the serious consequences of these breathing complications, the standard treatment for Parkinson’s (levodopa) has little to no effect on this aspect of the disease. Levodopa replenishes dopamine to help with movement, but it does not target the underlying processes of inflammation and cellular damage that drive non-movement-related deterioration.

This has left researchers searching for additional treatments that could address these gaps. Scientists were drawn to omega-3 fatty acids (the active ingredients in fish oil supplements) because of their well-known anti-inflammatory and antioxidant properties.

Led by Taina O. Macedo from the University of São Paulo in Brazil, the team utilized 52 mice to model the disease. The mice were divided into four groups: a healthy control group, a healthy group given omega-3, a Parkinson’s model group, and a Parkinson’s model group treated with omega-3.

To create the Parkinson’s model, researchers injected a chemical called 6-hydroxydopamine directly into the brain. Omega-3 supplementation began five days after the injections and continued for ten days—a deliberate timing choice, since by day five the dopamine cell damage was already well established, but the brainstem breathing regions had not yet fully deteriorated. Breathing was assessed using a specialized sealed chamber, and brain tissue was later examined under a microscope to count surviving neurons and assess immune cell activity.

As expected, the omega-3 supplements did not reverse or prevent the loss of dopamine-producing brain cells. However, in mice that received omega-3, the number of surviving neurons in the brainstem breathing regions was preserved at levels comparable to healthy control mice. Without omega-3, these same regions showed significant cell loss in Parkinson’s model animals.

The cellular environment also differed markedly. In the Parkinson’s model mice that did not receive omega-3, the brain’s immune cells showed signs of a reactive, inflammatory state in the brain’s breathing regions. There were also elevated levels of harmful reactive oxygen species, which are a marker of oxidative stress and cellular damage. Omega-3 treatment reduced this oxidative stress and attenuated the abnormal immune cell changes in these regions.

Crucially, these cellular protections translated into a measurable functional benefit. Parkinson’s model mice breathed significantly more slowly than healthy mice at rest—around 161 breaths per minute compared to 183 in controls. Omega-3-treated Parkinson’s mice, however, breathed at a rate of roughly 183 breaths per minute—statistically indistinguishable from the healthy animals.

The researchers noted in the paper that these protective effects “are likely attributable to the antioxidant and anti-inflammatory properties of omega-3 fatty acids,” and that the findings “reinforce the therapeutic potential of omega-3 in neurodegenerative conditions.”

The study carries important limitations. Results in animals do not always translate to humans—particularly for a complex disease. Human clinical trials would be needed before any conclusions can be drawn about whether omega-3 supplements could benefit people living with Parkinson’s disease.

The study, “Omega-3 supplementation prevents functional and neural respiratory damage present in an animal model of Parkinson’s disease,” was authored by Taina O. Macedo, Lais M. Cabral, Nicole C. Miranda, Fulvio A. Scorza, Thiago S. Moreira, and Ana C. Takakura.